Direct thrombin inhibitors.
Fritsma
George A
GA
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA. gfritsma@path.uab.edu
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D010875:Pipecolic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors*; D013927:Thrombosis / Q000517:prevention & control*; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D013449:Sulfonamides; D014859:Warfarin; D001120:Arginine; D013917:Thrombin; C031942:argatroban